Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Sodium Zirconium Cyclosilicate

Brand: Lokelma┬«
NICE TA: 599
Indication: For treating hyperkalaemia
Disease category: Blood and Nutrition
Commissioning responsibility: CCG
PbR excluded: No


1.1 Sodium zirconium cyclosilicate is recommended as an option for treating hyperkalaemia in adults only if used: in emergency care for acute life-threatening hyperkalaemia alongside standard care or in outpatient care for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they: have a confirmed serum potassium level of at least 6.0 mmol/litre are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia and are not on dialysis. Sodium zirconium cyclosilicate is recommended only if the company provides it according to the commercial arrangement.


LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA599 - Sodium Zirconium Cyclosilicate for treating Hyperkalaemia


Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG